Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Group",
"id" : "279340",
"meta" : {
"versionId" : "4",
"lastUpdated" : "2024-11-16T19:36:32.757Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 279340</b></p><a name=\"279340\"> </a><a name=\"hc279340\"> </a><a name=\"279340-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2024-11-16 19:36:32+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-conceptual-cohort-definition.html\">ConceptualCohortDefinition</a></p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340.)</p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/279340\">https://fevir.net/resources/Group/279340</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/279340</p><p><b>title</b>: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by Reference</span></p><p><b>value</b>: <a href=\"Group-279347.html\">CohortDefinition: T1DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by Reference</span></p><p><b>value</b>: <a href=\"Group-279346.html\">CohortDefinition: T2DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>\n</div></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340."
}
}
],
"url" : "https://fevir.net/resources/Group/279340",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "urn:ietf:rfc:3986",
"value" : "https://fevir.net/FOI/279340",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria",
"status" : "active",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"membership" : "conceptual",
"combinationMethod" : "any-of",
"characteristic" : [
{
"code" : {
"text" : "Defined by Reference"
},
"valueReference" : {
🔗 "reference" : "Group/279347",
"type" : "Group",
"display" : "CohortDefinition: T1DM-specific criteria"
},
"exclude" : false,
"description" : "T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening"
},
{
"code" : {
"text" : "Defined by Reference"
},
"valueReference" : {
🔗 "reference" : "Group/279346",
"type" : "Group",
"display" : "CohortDefinition: T2DM-specific criteria"
},
"exclude" : false,
"description" : "T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change